AR123560A1 - Ligandos de nlrx1 - Google Patents
Ligandos de nlrx1Info
- Publication number
- AR123560A1 AR123560A1 ARP210102616A ARP210102616A AR123560A1 AR 123560 A1 AR123560 A1 AR 123560A1 AR P210102616 A ARP210102616 A AR P210102616A AR P210102616 A ARP210102616 A AR P210102616A AR 123560 A1 AR123560 A1 AR 123560A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- ralk
- optionally
- ring
- Prior art date
Links
- 101001109452 Homo sapiens NLR family member X1 Proteins 0.000 title abstract 2
- 102100022697 NLR family member X1 Human genes 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005108 alkenylthio group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005109 alkynylthio group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 abstract 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, carboxyl Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 210000004901 leucine-rich repeat Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000006384 oligomerization reaction Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos que se dirigen al dominio de oligomerización de unión a nucleótidos, repetición rica en leucina que contiene la vía X1 (NLRX1). Los compuestos se pueden utilizar para tratar afecciones tales como enfermedades autoinmunes, enfermedades alérgicas, enfermedades crónicas y/o inflamatorias del sistema nervioso central, enfermedades respiratorias crónicas y/o inflamatorias, cáncer y enfermedades infecciosas. Las afecciones ejemplares incluyen la esclerosis múltiple, el asma, la enfermedad de Alzheimer, la enfermedad de Parkinson, una neuroinflamación resultante de, por ejemplo, accidente cerebrovascular, una lesión cerebral traumática o una lesión de la médula espinal, una enfermedad pulmonar obstructiva crónica, la fibrosis pulmonar idiopática y una enfermedad inflamatoria intestinal. Reivindicación 1: Un compuesto de la fórmula (1) que tiene un anillo A, un anillo B, un anillo C, un anillo D y un anillo E, o una sal o éster del mismo, en el que: A¹ y A⁵ son cada uno de manera independiente O, N(RA), N(RALK), C(RA)₂, C(RA) o N; A², A³ y A⁴ son cada uno de manera independiente O, N(RA), N(RALK), C(RA)₂, C(RA), N, C(RA)(RO), C(RO) o C(=O), con la condición de que A⁴ esté ausente de manera opcional; A⁶ y A⁷ son cada uno de manera independiente C(RA) o N; A⁸, A⁹ y A¹⁰ son cada uno de manera independiente O, N(RA), N(RALK), C(RA)₂, C(RA) o N; A¹¹, A¹², A¹³, A¹⁴ y A¹⁵ son cada uno de manera independiente O, N(RA), N(RALK), C(RA)₂, C(RA), N, C(RA)(RO), C(RO), o C(=O), con la condición de que A¹⁴ esté ausente de manera opcional; cada --- entre átomos adyacentes representa un enlace que está presente o ausente; L es O, N(RL) o C(RL)₂; RO en cada caso de manera independiente es hidroxilo o alquiloxi sustituido de manera opcional; RALK en cada caso de manera independiente es alquilo C₁-C₆; RA, RB y RL en cada caso de manera independiente es, hidrógeno, halógeno, alquilo sustituido de manera opcional, alquenilo sustituido de manera opcional, alquinilo sustituido de manera opcional, cicloalquilo sustituido de manera opcional, cicloalquenilo sustituido de manera opcional, hidroxilo, carboxilo, alquiloxi sustituido de manera opcional, alqueniloxi sustituido de manera opcional, alquiniloxi sustituido de manera opcional, cicloalquiloxi sustituido de manera opcional, cicloalqueniloxi sustituido de manera opcional, mercapto, alquiltio sustituido de manera opcional, alqueniltio sustituido de manera opcional, alquiniltio sustituido de manera opcional, alquilsulfinilo sustituido de manera opcional, alquilsulfonilo sustituido de manera opcional, alquilsulfoniloxi sustituido de manera opcional, cicloalquiltio sustituido de manera opcional, cicloalquilsulfinilo sustituido de manera opcional, cicloalquilsulfonilo sustituido de manera opcional, cicloalquilsulfoniloxi sustituido de manera opcional, cicloalqueniltio sustituido de manera opcional, cicloalquenilsulfinilo sustituido de manera opcional, cicloalquenilsulfonilo sustituido de manera opcional, cicloalquenilsulfoniloxi sustituido de manera opcional, amino sustituido de manera opcional, acilo, alquiloxicarbonilo sustituido de manera opcional, alqueniloxicarbonilo sustituido de manera opcional, alquiniloxicarbonilo sustituido de manera opcional, ariloxicarbonilo sustituido de manera opcional, carbamoilo sustituido de manera opcional, sulfamoilo sustituido de manera opcional, ciano, nitro, arilo sustituido de manera opcional, ariloxi sustituido de manera opcional, ariltio sustituido de manera opcional, arilsulfinilo sustituido de manera opcional, arilsulfonilo sustituido de manera opcional, arilsulfoniloxi sustituido de manera opcional, heteroarilo sustituido de manera opcional, heteroariloxi sustituido de manera opcional, heteroariltio sustituido de manera opcional, heteroarilsulfinilo sustituido de manera opcional, heteroarilsulfonilo sustituido de manera opcional, heteroarilsulfoniloxi sustituido de manera opcional, o un grupo heterocíclico no aromático sustituido de manera opcional.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081016P | 2020-09-21 | 2020-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123560A1 true AR123560A1 (es) | 2022-12-14 |
Family
ID=80739968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102616A AR123560A1 (es) | 2020-09-21 | 2021-09-21 | Ligandos de nlrx1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11548885B2 (es) |
| EP (1) | EP4196475A1 (es) |
| JP (1) | JP2023542921A (es) |
| KR (1) | KR20230074174A (es) |
| CN (1) | CN116368133A (es) |
| AR (1) | AR123560A1 (es) |
| AU (1) | AU2021342568A1 (es) |
| BR (1) | BR112023005189A2 (es) |
| CA (1) | CA3192644A1 (es) |
| CL (1) | CL2023000803A1 (es) |
| IL (1) | IL301346A (es) |
| MX (1) | MX2023003273A (es) |
| WO (1) | WO2022061224A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268399C (en) | 1996-10-31 | 2008-08-19 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| CA2293400A1 (en) | 1997-06-13 | 1998-12-17 | Gerald Mcmahon | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
| JPH1180110A (ja) | 1997-09-02 | 1999-03-26 | Fuji Photo Film Co Ltd | ジアゾニウム塩および感熱記録材料 |
| JP4244251B2 (ja) | 1999-02-22 | 2009-03-25 | 富士フイルム株式会社 | ジアゾ化合物および感熱記録材料 |
| US6197488B1 (en) | 1999-07-21 | 2001-03-06 | Eastman Kodak Company | Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AU2002217742B2 (en) | 2001-01-16 | 2008-02-21 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| JP2005511581A (ja) | 2001-11-07 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| BR0302965A (pt) | 2002-02-01 | 2005-02-09 | King Pharmaceuticals Res & Dev | Composto e método de tratar doenças mediadas por receptores de adenosina a2b |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| US8143285B2 (en) | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
| JP5030961B2 (ja) | 2005-10-11 | 2012-09-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク | 細胞のアポトーシスの検出および定量化用の化合物およびキット |
| NZ546477A (en) | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| WO2012087938A1 (en) * | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| PH12019500143A1 (en) | 2013-08-23 | 2020-03-02 | Neupharma Inc | Certain chemical entities, compositions, and methods |
| CN109134434B (zh) | 2017-11-06 | 2021-02-19 | 北京大学深圳研究生院 | 喹啉或喹唑啉类化合物及其制备方法和应用 |
| US10487057B1 (en) * | 2018-07-05 | 2019-11-26 | Landos Biopharma, Inc. | NLRX1 ligands |
-
2021
- 2021-09-20 KR KR1020237012417A patent/KR20230074174A/ko unknown
- 2021-09-20 BR BR112023005189A patent/BR112023005189A2/pt unknown
- 2021-09-20 CN CN202180064577.7A patent/CN116368133A/zh active Pending
- 2021-09-20 MX MX2023003273A patent/MX2023003273A/es unknown
- 2021-09-20 IL IL301346A patent/IL301346A/en unknown
- 2021-09-20 JP JP2023518124A patent/JP2023542921A/ja active Pending
- 2021-09-20 US US17/479,337 patent/US11548885B2/en active Active
- 2021-09-20 CA CA3192644A patent/CA3192644A1/en active Pending
- 2021-09-20 EP EP21790019.0A patent/EP4196475A1/en active Pending
- 2021-09-20 AU AU2021342568A patent/AU2021342568A1/en active Pending
- 2021-09-20 WO PCT/US2021/051068 patent/WO2022061224A1/en active Application Filing
- 2021-09-21 AR ARP210102616A patent/AR123560A1/es unknown
-
2022
- 2022-12-20 US US18/085,293 patent/US20230128450A1/en active Pending
-
2023
- 2023-03-20 CL CL2023000803A patent/CL2023000803A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021342568A1 (en) | 2023-04-20 |
| US11548885B2 (en) | 2023-01-10 |
| IL301346A (en) | 2023-05-01 |
| MX2023003273A (es) | 2023-04-26 |
| US20220089586A1 (en) | 2022-03-24 |
| CN116368133A (zh) | 2023-06-30 |
| BR112023005189A2 (pt) | 2023-04-25 |
| CL2023000803A1 (es) | 2023-11-17 |
| CA3192644A1 (en) | 2022-03-24 |
| KR20230074174A (ko) | 2023-05-26 |
| US20230128450A1 (en) | 2023-04-27 |
| WO2022061224A1 (en) | 2022-03-24 |
| EP4196475A1 (en) | 2023-06-21 |
| JP2023542921A (ja) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trcek et al. | Germ granules in Drosophila | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| CA2843609C (en) | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | |
| PE20200401A1 (es) | Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos | |
| CA2915817C (en) | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | |
| BR112018006448A2 (pt) | derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos | |
| BR112022025201A2 (pt) | Compostos de sulfonamida de di-hidroquinolina de ciclobutila | |
| BR112015012454A2 (pt) | compostos úteis como inibidores de atr cinase | |
| UY35156A (es) | Derivados del ácido indaniloxi dihidrobenzofuranil acético como agonistas de las gpr40 | |
| BR112013029692A2 (pt) | derivados de imidazol úteis para o tratamento da artrite | |
| BRPI0513286A (pt) | compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| CO2017012545A2 (es) | Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ) | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| AR063878A1 (es) | Compuestos de pirrol-piridina y composicion farmaceutica | |
| EA201490888A1 (ru) | Новые производные пурина и их применение для лечения заболевания | |
| BR112015001028A2 (pt) | antagonistas de receptor 5-ht3 | |
| Cherukuvada et al. | 4-Aminosalicylic acid adducts | |
| UY33191A (es) | Derivados de pirazina | |
| BR112019014235A2 (pt) | Inibidores bicíclicos de histona desacetilase | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| WO2017019875A1 (en) | Anthracene-9, 10-dione dioxime compounds prodrugs and their uses | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| PE20220167A1 (es) | COMPUESTOS PIPERIDINIL BICICLICOS FUSIONADOS Y RELACIONADOS COMO MODULADORES DEL RECEPTOR C5a |